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Abstract 
Aims 
Bcl2 associated transcription factor (BCLAF1) is a nuclear protein that binds to bcl 
related proteins and can induce apoptosis and autophagy.  This study has investigated the 
expression of BCLAF1 in a series of rectal cancers following neoadjuvant therapy. 
 
Methods and results 
Immunohistochemistry was performed on a post-neoadjuvant therapy rectal cancer 
tissue microarray.  It contained rectal cancers (n=248), lymph node metastasis (n=76) and 
non-neoplastic rectal mucosal samples (n=73).  A monoclonal antibody which we have 
developed to BCLAF1 was used.  
Non-neoplastic rectal epithelium showed nuclear localisation of BCLAF1 in both 
crypt and surface epithelial cells whereas rectal cancers showed both nuclear and cytoplasmic 
BCLAF1 expression.  Most rectal cancers showed moderate or strong nuclear 
immunoreactivity but showed weak cytoplasmic immunoreactivity.  Cytoplasmic BCLAF1 
expression was increased in primary rectal cancers compared with non-neoplastic rectal 
mucosa (p=0.008).  Negative and weak nuclear BCLAF1 expression was associated with 
poor prognosis (HR=0.502, 95%CI=0.269-0.939, χP2P=4.876, p=0.027).  Nuclear BCLAF1 was 
independently prognostic in a multivariate model (HR=0.431, 95%CI=0.221-0.840, p=0.013). 
 
Conclusions 
This study has shown that both cytoplasmic and nuclear BCLAF1 are increased in 
post neoadjuvant therapy rectal cancer and that negative and weak nuclear BCLAF1 
expression is independently associated with poor prognosis. 
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Introduction 
Colorectal cancer is one of the commonest types of cancer with an increasing 
incidence.  While primary surgery remains the mainstay of colon cancer treatment, rectal 
cancer is increasingly being treated by neoadjuvant chemo-radiotherapy to down stage the 
tumour and increase the opportunity for curative surgery.  There are also studies suggesting 
that in some circumstances, after pelvic chemo-radiotherapy and close clinical & imaging 
follow up, surgery can be used as a ‘salvage’ procedure in those patients that relapse.  High 
resolution pelvic MRI is used to guide patient selection for neoadjuvant therapy using criteria 
including high stage tumours, possible involvement of circumferential resection margin 
(CRM) and the presence of extramural vascular invasion.  In rectal cancer neoadjuvant 
therapy can achieve a 25% complete pathological response rate, with approximately 65% of 
tumours showing some response to chemo-radiotherapy.  Approximately 10% of patients 
show no significant response to such therapy. P1-4P  The outcome in patients with a complete 
pathological response appears to be good with a very low rate of local recurrence.  The 
position regarding those patients whose tumours do not show a complete response is less 
certain, as is the value of adjuvant chemotherapy.  There is still a requirement for prognostic 
as well as predictive markers biomarkers in those patients, to aid decisions around the use of 
adjuvant chemotherapy.  
Bcl2 associated transcription factor (BCLAF1) is a nuclear protein whose homologue 
(btf) was originally identified in a screen of adenovirus proteins that binds to bcl related 
proteins. P5P  Studies have shown that BCLAF1 can induce apoptosis, autophagy and repress 
transcription. P6P  It has also been suggested to have cellular roles including the regulation of T 
cell activation and mRNA distribution which are distinct from its interactions with bcl related 
proteins. P7,8P  
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This study has investigated the expression of bcl2 associated transcription factor 
(BCLAF1) in a series of rectal cancers following neoadjuvant therapy using a well 
characterised rectal cancer tissue microarray. 
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Materials and methods 
Development of BCLAF1 monoclonal antibody 
A monoclonal antibody to BCLAF1 was produced in collaboration with Vertebrate 
Antibodies Ltd (Aberdeen, UK) using a synthetic peptide as the immunogen.  Briefly, a 10 
amino acid sequence (KYQGDGIVED) corresponding to amino acids 891-900 of the 
BCLAF1 sequence was identified which was antigenic, exposed on the surface and unique to 
the target protein.  The amino acid sequence lies in a region of the protein which is present in 
all the splice variants of BCLAF1.  The peptide was obtained commercially (Almac Sciences 
Ltd, East Lothian, UK) and conjugated to ovalbumin for the immunisation and bovine serum 
albumin for ELISA. P9,10P  The immunisation of mice, production of hybridoma cells and 
ELISA screening were carried out essentially as described previously. P9,10P  The hybridomas 
were cloned by limiting dilution until a single ELISA positive colony was grown in a 96 well 
plate.  The hybridoma cell line designated M33-P5B11 was then grown at high cell density 
for the preparation of antibody stock which was used subsequently for its characterisation by 
immunoblotting and immunohistochemistry. 
 
Immunoblotting 
Whole cell lysate from cells (human embryonic kidney cells) overexpressing 
BCLAF1 was used as positive control for immunoblotting while lysate from cells containing 
vector only was used as a negative control. The lysates were bought from (Novus Biologicals, 
Cambridge, UK).  Cell lysates (5μg protein/lane) were resolved by electrophoresis on 
NuPAGE 4-12% Bis-Tris gels (Fisher Scientific, Loughborough, UK,).  The membranes 
were blocked for 1 hour at room temp in PBS-Tween-20 (PBST) containing 3% (w/v) skim 
milk powder.  Blots were incubated overnight at 4 C with anti-BCLAF1 monoclonal antibody 
diluted in PBST (1/2 dilution).  Membranes were washed (6 times) for 1 hour in 1% skim 
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milk.  Blots were subsequently probed for 1 hour with a secondary antibody conjugated 
horseradish-peroxidase-conjugated anti-mouse IgG (Sigma-Aldrich, Dorset, UK) (1:2000). 
The membranes were washed (6 times) for 1 hour in 1% skim milk and protein bands 
visualized using the enhanced chemiluminescence detection system (Fisher Scientific). 
 
Patient cohort 
A tissue microarray was constructed to include samples from 321 patients recruited 
consecutively over a seven-year period (2005-2011).  Each of these patients had a surgical 
resection of a primary rectal tumour which had been treated with neoadjuvant therapy prior to 
surgery (table 1). The neoadjuvant treatment was 5 weeks of pelvic radiotherapy, using 
intravenous contrast and CT planning with the diagnostic thin slice MRI scan fused with the 
planning CT scan to aid in identification of the tumour. Using these images the oncologist 
(LMS) contoured the relevant anatomy to be treated (primary tumour plus a margin, local 
mesorectal lymph nodes and lymph nodes following the internal iliac artery up to the S1/S2 
vertebral area). The dose prescribed was 45Gy to the 100% isodose point, and this was 
delivered in 25 daily fractions of 1.8Gy, Monday to Friday for 5 weeks. Concurrent 
chemotherapy, using oral capecitabine (825mg/m2 bd) was also taken by the patients on the 
same days (Monday to Friday) as the radiotherapy for 5 weeks. Surgery was scheduled for 
about 8 to 10 weeks after completion of the neoadjuvant therapy. Repeat imaging of the 
pelvis with thin slice MRI was only carried out on a minority of the patients whose tumours 
on the diagnostic imaging suggested they were initially inoperable, as opposed to those who 
were at risk of having an involved circumferential resection margin but would be otherwise 
resectable.  
Adjuvant therapy was considered for patients who had adverse pathological factors 
including poor differentiation, extramural vascular invasion, lymph node metastases, 
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involved CRM, partial or minimal response to neoadjuvant therapy in their resected rectal 
cancer specimen. 
The resected rectal cancer specimens were opened anteriorly along the anti-
mesenteric border of the sigmoid colon, washed in water and fixed in formalin for at least 48 
hours.  The rectum was left intact to facilitate assessment of potential serosal surface 
involvement and circumferential margin involvement.  The fixed specimens were then further 
dissected and appropriate tissue blocks taken for histopathological assessment according to 
the guidelines of The Royal College Pathologists for reporting of colorectal cancer excision 
specimens. P11 P   Appropriate guidance from TNM5 was also followed and reported by an 
expert gastro-intestinal pathologist (GIM). 
The response of rectal cancer to neoadjuvant therapy was assessed using the following 
parameters: i) Proportion of residual histologically viable tumour and ii) the degree of 
fibrosis and inflammation associated with the residual viable tumour.  These parameters were 
incorporated into a four point scale to make an overall assessment of the response of the 
tumour to pre-operative therapy (complete response, good partial response, partial response 
and minimal response).  This histopathological response classification shows a strong 
correlation with survival in this cohort (figure 1). 
Tumour tissue samples were obtained from 248 primary tumours and 76 lymph node 
metastases.  The rectal cancer tissue microarray was constructed as previously described and 
contained two 1mm cores of tissue from each primary tumour. P12,13P  Samples from complete 
pathological responders to therapy (n=73) were treated as examples of normal mucosa 
because they were obtained from the site of the original primary tumour but showed no 
evidence of malignancy upon histopathological examination.  Lymph node metastases were 
also sampled from tumours with metastatic disease to permit comparison between primary 
and metastatic tumours.  
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Survival information (all cause mortality) was available for all patients and at the time 
of censoring patient outcome data there had been 56 (17.4%) deaths.  The mean patient 
survival was 72 months (95% CI 68-75 months). 
 
Immunohistochemistry 
Immunohistochemistry for BCLAF1 was performed with the biotin-free Dako 
Envision™ system (Dako, Ely, UK) using a Dako autostainer (Dako) as previously 
described. P12-14P  The sections were evaluated by light microscopic examination and the 
intensity of immunostaining in each core assessed independently by two investigators (GTB 
and GIM) using a scoring system previously described for the assessment of protein 
expression in tumour microarrays. P12-14P  The intensity of immunostaining in each core was 
scored as negative, weak, moderate or strong.  The sub-cellular localisation (nuclear, 
cytoplasmic or membranous) of the immunostaining was also recorded.  Variation in 
immunostaining between cores of each case was not identified.  Any discrepancies in the 
immunohistochemical assessment of the tissue cores between the two observers were 
resolved by simultaneous microscopic re-evaluation. 
 
Statistics 
Statistical analysis of the data including the Mann-Whitney U test, Wilcoxon signed 
rank test, chi-squared test, Kaplan-Meier survival analysis, log-rank test and Cox multi-
variate analysis (variables entered as categorical variables) including the calculation of 
hazard ratios and 95% confidence intervals was performed using IBM SPSS version 21 for 
Windows 7 (IBM, Portsmouth, UK).  The log rank test was used to determine survival 
differences between individual groups.  A probability value of p≤0.05 was regarded as 
significant.  The influence of different cut-off points in relation to survival was investigated 
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by dichotomizing the intensity score for BCLAF1.  The groups that were analysed were 
negative staining versus any positive staining, negative and weak staining versus moderate 
and strong staining and negative, weak and moderate staining versus strong staining. 
 
Ethics 
The project had the approval of The North of Scotland research ethics committee (ref. 
nos. 08/S0801/81 and 11/NS/0015).  The research ethics committee did not require written 
patient consent for the retrospective tissue samples that were included in the rectal cancer 
tissue microarray. 
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Results 
Monoclonal antibody 
The specificity of the monoclonal antibody to BCLAF1 was determined by ELISA 
using the immunogenic peptide and also by immunoblotting using BCLAF1 overexpressed 
cell lysate.  A band migrating at the expected molecular weight (110kDa) was observed in the 
lane containing the BCLAF1 overexpressed cell lysates and no band was observed in the lane 
containing vector only (figure 2). 
 
BCLAF1 expression in rectal cancer 
BCLAF1 showed a nuclear localisation in non-neoplastic rectal epithelium while in 
rectal cancer there was both nuclear and cytoplasmic immunoreactivity (figure 3).  Nuclear 
BCLAF1 expression was increased in primary rectal cancers compared with normal rectal 
mucosa (table 2 and figure 4).  There was also a difference between expression of nuclear 
BCLAF1 in primary rectal cancer and metastatic rectal cancer (p=0.05).  However, when 
paired primary and metastatic tumours were compared there was no significant difference 
between nuclear BCLAF1 expression.  Cytoplasmic BCLAF1 expression showed a 
significant decrease in expression between primary and metastatic tumours (p=0.008) and 
also in paired primary and metastatic rectal cancers (p=0.033). 
 
Relationship of BCLAF1 with pathological parameters 
Nuclear BCLAF1 showed a strong relationship with Dukes stage (χP2P=19.134, 
p=0.004).  There were no other significant relationships between BCLAF1 and pathological 
parameters including tumour stage, lymph node stage and extramural vascular invasion (table 
3). 
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Survival analysis 
There was a trend towards significance for overall nuclear BCLAF1 expression 
(χP2P=6.334, p=0.096).  When the nuclear BCLAF1 immunohistochemical scores were 
dichotomised then there was a significant relationship between nuclear BCLAF1 expression 
and overall survival when negative and weak BCLAF expression was compared with 
moderate and strong BCLAF1 expression (table 4 and figure 5).  Comparing nuclear BCLAF 
negative and weakly positive tumours with nuclear BCLAF1 moderate and strong expressing 
tumours showed that there was a highly significant association with survival (HR=0.502, 
95%CI=0.269-0.939, χP2P=4.876, p=0.027).  Mean survival for the negative/weak group of 
tumours (n=55) was 57 months (95%CI=48-66 months) while the mean survival for the 
moderate/strong group of tumours (n=125) was 70 months (95%CI=63-72 months).  Nuclear 
BCLAF1 was independently prognostic in two multivariate models (table 5A and table 5B); 
one which included Dukes stage (HR=0.431, 95%CI=0.221-0.840, p=0.013) and the other 
which contained ypTstage and ypNstage (HR=0.451, 95%CI=0.229-0.891, p=0.022) as the 
parameters to assess tumour stage. 
There were no significant relationships between cytoplasmic BCLAF1 expression and 
survival. 
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Discussion 
This study of a large series of post therapy rectal cancers with good follow-up treated 
by neoadjuvant chemo-radio therapy has shown that strong nuclear expression of BCLAF1 in 
post-treatment rectal cancer cells is associated with increased patient survival.  Neoadjuvant 
chemo-radio therapy is now the standard treatment for rectal cancer judged by thin slice MRI 
to be at high risk of an involved circumferential resection margin and thus local and systemic 
recurrence and there is a clear requirement to identify biomarkers of not only prognosis 
following neoadjuvant chemo-radiotherapy but also the patients who may benefit from post-
operative adjuvant chemotherapy. P4 P However, there have been relatively few previous studies 
of post treatment rectal cancers to identify biomarkers of outcome following neoadjuvant 
therapy.  Those studies have generally been limited as they have been performed on relatively 
small numbers of cases and often with only short term follow-up. 
BCLAF1 is a nuclear protein that was originally identified in yeast and was shown to 
interact with Bcl2 family of proteins and to promote apoptosis. P5,15 P It was also hypothesised 
that BCLAF may repress the transcription of survival genes through P53 inhibition 
suggesting that BCLAF1 plays critical role in determining cell fate.P 5,15  PFurthermore, it was 
demonstrated that BCLAF1 regulates apoptosis related proteins such as Mdm2, p53, BAX 
and Bcl-2 in HCT116 human colon adenocarcinoma cells. P16P  BCLAF1 has also been 
proposed to have a variety of other cellular functions.P  5-7, 17,18 
Our data has shown that BCLAF1 localisation was almost exclusive nuclear 
localisation in non-neoplastic rectal epithelium while in rectal cancer there was both nuclear 
and cytoplasmic BCLAF1 immunoreactivity.  Nuclear localisation of BCLAF1 is expected. P6P 
What is interesting and not previously described is the cytoplasmic localisation of BCLAF1 
in rectal cancers.  The aberrant sub-cellular localisation in tumours of proteins that show 
nuclear expression in normal cells has also been observed for other putative tumour 
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biomarkers.  For example hnRNPK showed aberrant cytoplasmic expression in colorectal 
cancer indicative of abnormal protein processing in tumour cells. P12,19,20P  Similarly cellular 
apoptosis susceptibility protein (CSE1L) which is involved in the control of cell proliferation 
has also been shown to have aberrant expression in colorectal cancer cells. P21P  This is 
indicative of altered protein processing and signalling in tumour cells.  
BCLAF1 has not previously been studied in tumours although it has recently been 
identified as being induced in radiation exposed cells and to promote apoptosis. P18  PMoreover, 
our study also revealed that strong nuclear BCLAF1 expression independently correlated 
with better survival outcome among rectal cancer patients.  Such observations are consistent 
with current knowledge. BCLAF1 has been proven to induce apoptosis in highly irradiated 
cell lines that have been deemed irreparable by disrupting inhibition of a p21-mediated 
apoptotic pathway, which is commonly dysfunctional in tumour cells.  Furthermore, tumour 
cells were found to suppress BCLAF1 triggering a cascade of anti-apoptotic cellular events 
that contribute to tumour radiation resistance, defective DNA repair pathways and increased 
capacity for tumour cell survival. P18P  An increased level of nuclear BCLAF1 in rectal cancer 
will induce apoptosis and subsequently lead to improved survival outcome. 
In spite of substantial efforts to identify novel prognostic biomarkers in rectal cancer 
patients, only few putative biomarkers have been identified.P 22 PThe putative stem cell marker 
aldehyde dehydrogenase 1 (ALDH1) has been studied by immunohistochemistry in post 
treatment tumour samples from 46 patients with rectal cancer who had received neoadjuvant 
chemo-radiotherapy.  High cytoplasmic ALDH1 in post-operative tumour samples was 
independently associated with a shorter disease free interval and disease specific survival. P23P 
In a separate study of 64 patients ALDH1expresion as assessed by immunohistochemistry in 
post therapy rectal cancers was also shown to be associated with increased risk of recurrence 
and poor survival. P24P  
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Another putative stem cell marker, CD 133, has been identified in post therapy rectal 
tumour samples from 40 patients who had received neoadjuvant chemo-radiotherapy.  High 
CD133 as assessed by immunohistochemistry was associated with a higher rate of recurrence 
and decreased disease-free survival and was proposed to be a marker of a treatment resistance 
phenotype in post therapy tumour cells. P25P One more further biomarker showing prognostic 
potential and was associated with shorter relapse free survival and survival is the chemokine 
receptor CXCR4. P26P  This receptor has recently been studied in the post resection samples of 
68 patients who had received neoadjuvant therapy for rectal cancer and high CXCR4 was 
associated with shorter relapse free survival and survival. P26 
In conclusion this study has shown that BCLAF1 is overexpressed in post therapy 
rectal cancer cells and its subcellular localisation is aberrant; in normal rectal mucosa 
BCLAF1 is exclusively nuclear whereas in tumour cells BCLAF1 was present both in the 
cytoplasm and the nucleus.  The study has also shown that strong nuclear BCLAF1 
immunoreactivity in post therapy rectal cancer is associated with increased patient survival 
and is an independent prognostic factor. 
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Table 1. 
Clinicopathological characteristics of the patients and their tumours included in the rectal 
cancer tissue microarray 
 
  Percent 
(number) 
Mean 
survival 
(months, 
95% CI) 
Relationship with survival, 
hazard ratio and 95% CI 
Sex     
 Male 61% (196) 71 (66-76) χP2P =0.083, p=0.774, 
HR=1.081 (0.635-1.814) 
 Female 39% (125) 71 (67-75)  
Age 
(mean:range) 
 (66:29-91)   
 < 70 62% (200) 76 (73-80) χP2P=14.758, p=<0.001, 
HR=2.730 (1.597-4.669) 
 ≥ 70 38% (121) 63 (57-69)  
Tumour 
differentiation 
    
 Well/moderate 73.8% (237) 69 (65-72) Well/moderate v poor 
χP2P=29.789, p=<0.001, 
HR=2.500 (1.712-3.652) 
 Poor 3.4% (11) 27 (6-48) Well/moderate v no residual 
tumour  χP2P=13.651, 
p=<0.001, HR=15.765 
(2.175-114.282) 
 No residual 
tumour 
22.7% (73) 83 (80-87)  
ypT stage     
 yT0 24.9% (80) 83 (79-86) T0 v T1  χP2P=0.137, p=0. 711 
HR=0.715 (0.119-4.285) 
 yT1 11.2% (36) 70 (66-74) T1 v T2  χP2P=2.899, p=0.089, 
HR=0.153 (0.003-6.744) 
 yT2 21.5% (69) 71 (64-77) T2 v T3  χP2P=3.391, p=0.066, 
HR=1.436 (0.897-2.297) 
 yT3 39.6% (127) 
 
63 (57-69) T3 v T4  χP2P=10.022, 
p=0.002, HR=0.490 (0.303-
0.794) 
 yT4 2.8% (9) 30 (17-43)  
ypN stage     
 yN0 76.3% (245) 75 (72-79) N0 v N1  χP2P=7.393, 
p=0.007, HR= 0.401(0.216-
0.744) 
 yN1 17.1% (55) 62 (53-71) N1 v N2  χP2P= 5.984, 
p=0.014, HR=0.367 (0.159-
0.850) 
 yN2 6.5% (21) 37 (25-48)  
EMVI     
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P
1
Pcases with a pathological complete response (path CR) where Dukes staging is not 
appropriate 
  
 Present 8.7% (28) 35 (25-46) present v absent  χP2P=56.209, 
p=<0.001, HR=0.146 
(0.081-0.262) 
 Absent 91.3% (293) 75 (71-78)  
Dukes stage     
 A 28% (90) 76 (71-81) Dukes A v Dukes B  
χP2P=9.673, p=0.002, 
HR=0.557 (0.376-0.824) 
 B 25.5% (82) 59 (53-65) Dukes B v Dukes C  
χP2P=1.383, p=0.240, 
HR=0.837 (0.626-1.119) 
 C 23.7% (74) 57 (49-66)  
 naP1 22.7% (73) 84 (83-87) Path CR v Dukes A  
χP2P=0.137, p=0. 711 
HR=0.715 (0.119-4.285) 
Response to 
neoadjuvant 
therapy 
    
 Complete  22.7% (73) 84 (81-87) Complete v good partial  
χP2P=5.995, p=0.014, 
HR=0.493 (0.233-1.042) 
 Good Partial 35.5% (114) 75 (71-80) Good partial v partial  
χP2P=11.908, p=0.001, 
HR=0.548 (0.392-0.767) 
 Partial 30.5% (98) 60 (54-67) Minimal v partial  χP2P=0.364, 
HR=1.108 (0.792-1.549) 
 Minimal 11.2% (36) 50 (41-59)  
Excision     
 No 11.5% (37) 41 (34-49) χP2P=19.983, p=<0.001, HR= 
4.54 (2.529-8.150) 
 Yes 88.5% (284) 74 (71-78)  
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Table 2.  Comparison of cytoplasmic and nuclear BCLAF expression in rectal mucosa, primary rectal cancer and lymph node metastasis. 
 
 
 Immunoreactivity 
(p value, normal v 
primary tumour) 
Change in 
expression 
in tumour 
Immunoreactivity 
(p-value primary 
tumour v lymph 
node metastasis) 
Change in 
expression in 
lymph node 
metastasis 
Immunoreactivity (p value, 
paired primary Dukes C 
tumour v lymph node 
metastasis) 
Change in expression 
in lymph node 
metastasis 
BCLAFc <0.001 ↑ 0.008 ↓ 0.033 ↓ 
BCLAFn 0.097 - 0.05 ↓ 0.336 - 
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Table 3.  The relationship of cytoplasmic and nuclear BCLAF1 with pathological parameters. 
 
 Tumour differentiation EMVI ypT stage ypN stage Dukes stage Response to 
neoadjuvant therapy 
 χP2 p value χP2 p value χP2 p 
value 
χP2 p value χP2 p value χP2 p value 
Cytoplasmic 
BCLAF1 
 
2.633 0.268 2.688 0.261 3.736 0.712 1.852 0.763 1.860 0.761 6.873 0.143 
Nuclear 
BCLAF1 
 
0.695 0.874 5.330 0.149 14.850 0.095 10.235 0.115 19.134 0.004 5.699 0.458 
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Table 4.  The relationship of nuclear and cytoplasmic BCLAF1 with survival. 
 
 
Cut-off point 
 Overall Negative v weak, 
moderate and strong 
Negative and weak v moderate 
and strong  
Negative, weak and moderate v 
strong 
 χP2 p value χP2 p value χP2 p value χP2 p value 
Cytoplasmic 
BCLAF1 
0.065 0.968 0.004 0.952 3.642 0.056 - - 
Nuclear 
BCLAF1 
6.334 0.096 0.389 0.533 4.876 0.027 0.426 0.514 
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Table 5.  The significance of nuclear BCLAF1 expression in multivariate analysis in patients 
with residual tumour.  Two models are shown including either Dukes stage (model A) or 
yTstage and yNstage (model B) as the parameters for assessing tumour stage. 
 
A. Model including Dukes stage 
Variable (categories) Wald value p-value Hazard ratio (95%CI) 
Age (< 70 v ≥ 70) 2.262 0.133 1.025 (0.993-1.058) 
Gender (male v female) 0.999 0.318 1.410 (0.719-2.764) 
Tumour differentiation 
(well/moderate v poor) 
9.060 0.003 0.178 (0.058-0.548) 
EMVI (present v absent) 5.844 0.016 0.360 (0.157-0.824) 
Dukes stage (A v B v C) 2.663 0.264 0.492 (0.164-2.444) 
Response to neoadjuvant 
therapy (good partial v 
partial v minimal) 
2.032 0.362 0.554 (0.233-2.428) 
Adjuvant therapy (yes v 
no) 
0.983 0.321 1.567 (0.645-3.809) 
Nuclear BCLAF1 
(negative/weak v 
moderate/strong) 
6.104 0.013 0.431 (0.221-0840) 
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B. Model including tumour stage and lymph node stage 
Variable (categories) Wald value p-value Hazard ratio (95%CI) 
Age (< 70 v ≥ 70) 3.943 0.047 1.034 (1.000-1.068) 
Gender (male v female) 0.700 0.403 1.348 (0.669-2.715) 
Tumour differentiation 
(well/moderate v poor) 
5.850 0.016 0.236 (0.073-0.761) 
Tumour (ypT) stage 
(yT1 v yT2 v yT3 v yT4) 
3.815 0.432 0.382 (0.010-5.490) 
Nodal (ypN) stage 
(yN0 v yN1 v yN2) 
3.185 0.203 0.440 (0.127-1.260) 
EMVI (present v absent) 4.835 0.028 0.367 (0.150-0.897) 
Response to neoadjuvant 
therapy (good partial v 
partial v minimal) 
3.381 0.184 0.437 (0.180-2.128) 
Adjuvant therapy (yes v 
no) 
0.872 0.350 1.601 (0.596-4.301) 
Nuclear BCLAF1 
(negative/weak v 
moderate/strong) 
5.259 0.022 0.451 (0.229-0.891) 
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Figure legends 
Figure 1. 
The relationship of histopathological response grade and overall survival in rectal cancer. 
 
Figure 2. 
Immunoblot of BCLAF1.  A band migrating at the expected molecular weight (110kDa) is 
observed in the lane containing the BCLAF1 overexpressed cell lysates (+) and no band is 
observed in the lane containing vector only (-). 
 
Figure 3. 
Immunohistochemical localisation of BCLAF1 in non-neoplastic rectal mucosa (A and B), 
primary rectal cancer following neoadjuvant therapy (C and D) and lymph node metastasis (E 
and F). A, C and E are low power photomicrographs and the area within each rectangle is 
shown at high magnification in panels B, D and F respectively. 
 
Figure 4. 
The frequency of nuclear and cytoplasmic BCLAF1 in non-neoplastic rectal mucosa, primary 
rectal cancer following neoadjuvant therapy and lymph node metastasis. 
 
Figure 5. 
The relationship of nuclear BCLAF1 (BCLAF1n) expression and overall survival in rectal 
cancer. 
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